Xalkori(crizotinib) of Pfizer and Pemrolizumab of Merck combination dug potential to be explored in phase 1 clinical study in which the Safety and Tolerability of this combination in patients with ALK+ advanced or metastatic non -small cell lung cancer (NSCLC) is to to evaluated.
Individually , Crizotininb(Xalkori) inhibits an abnormally activated enzyme in patients with ALK+ metastatic lung cancer , and pembrolizumab (investigational drug) harnesses body immune system to fight Cancer. Permbrolizumab exerts dual ligand blockade of Programmed cell death protein 1(PD-1) on T lymphocytes(T-cells) with its ligands PD-L1 and PD-L2.
Individually , Crizotininb(Xalkori) inhibits an abnormally activated enzyme in patients with ALK+ metastatic lung cancer , and pembrolizumab (investigational drug) harnesses body immune system to fight Cancer. Permbrolizumab exerts dual ligand blockade of Programmed cell death protein 1(PD-1) on T lymphocytes(T-cells) with its ligands PD-L1 and PD-L2.